Founder Intake
Leadership
Managing Partner
Track Record
PhD in Atomic and Molecular Physics (Fulbright Scholar, UC Berkeley); MBA, MIT Sloan.
Two successful AI-Bio exits (M&A Lead and IPO collaboration).
Formerly Head of Business Development, Oncology and Genomics at Roche.
Global BD, leading turnarounds for underperforming markets at Cepheid (Danaher).
Former Monitor Deloitte (Pharma Strategy); Global BD, CDx Pharma at Thermo Fisher Scientific.
Building alongside founders who refuse to accept the current limits of what is possible.
The Human Element
We back founders with resilience, drive, and hunger who are ready to solve profitable unmet needs. Breakthroughs are not just a result of better code or faster physics, but of the relentless execution of individuals who refuse to accept the current limits of what is possible.
The Thesis
We do not look for trends. We leverage the most appropriate deep technologies available, including but not only AI and Quantum Computing, to solve mission critical unmet needs.
When traditional sciences reach their limits, we bridge the gap with the best technology available or we create it. Today's most pressing problems are no longer solvable through legacy scientific silos. They demand an interdisciplinary architecture that integrates the most advanced tools of our time.
Strategic Pillars
Techbio
Leveraging AI across every stage of discovery and development to engineer better medicines, increasing their probability of success to save and improve lives.
Biotech
We are interested in several indications including oncology, CNS, women's health, and cardiometabolic, among others. Our final objective is longevity: focusing on the science required to ensure people do not just live longer, but live better.
Tech
We are interested in the technologies that can be leveraged to improve our areas of interest.
Quantum
Backing the subatomic operating systems of the future. We utilize the software layers required to calculate molecular interactions with a degree of Chemical Accuracy and speed that classical compute cannot reach.
Building within these pillars?
Beyond the Pillars
Building something that defies categorization? If you have a breakthrough with industrial-scale potential, we want to see it.
The Venture Model
Integrating science based breakthroughs into industrial workflows to accelerate unmet needs solutions.
Using advanced software to compress development timelines and reduce the cost of failure.
Building companies specifically designed to solve the innovation gap for global pharmaceutical and technology leaders.
Restricted
Corporate
Accelerating Enterprise Alpha and Strategic Moats
Beyond identifying breakthroughs that align with specific corporate mandates, we deliver the vetted technical architectures required for immediate industrial-scale deployment.
We eliminate the Innovation Lag that penalizes public market valuations. By providing engineering pathways for strategic acquisition, we reduce capital expenditure and accelerate time-to-value.
We do not just find technology. We provide the turnkey integration that strengthens a company's competitive position and drives long-term shareholder value.
Get in Touch
For M&A leaders, R&D executives, and strategic partners seeking to de-risk industrial-scale deployment.